Bespoke Extracts (BSPK) Cash from Investing Activities (2012 - 2022)

Bespoke Extracts (BSPK) reported Cash from Investing Activities of -$48519.0 for Q4 2022, down 10445.2% sequentially from $469.0 in Q3 2022.

Bespoke Extracts (BSPK) Cash from Investing Activities (2012 - 2022) Analysis & Trends

Bespoke Extracts (BSPK) has 8 years of Cash from Investing Activities data on file, last reported at -$48519.0 in Q4 2022.

For the quarter ending Q4 2022, Cash from Investing Activities changed N/A year-over-year to -$48519.0; the trailing twelve-month figure through Dec 2022 stood at -$87971.0 (changed N/A YoY), and the FY2022 full-year result was -$87971.0, changed N/A from the prior year.
Cash from Investing Activities slipped to -$48519.0 in Q4 2022, from $469.0 in the prior quarter.
In the past five years, Cash from Investing Activities ranged from a high of $469.0 in Q3 2022 to a low of -$48519.0 in Q4 2022.
A 3-year average of -$15494.3 and a median of -$4398.0 in 2021 frame the typical range for Cash from Investing Activities.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Investing Activities (Qtr)
1	Haleon	89.78 Bn	87.91 Bn	-	-
2	Teva Pharmaceutical Industries	35.95 Bn	32.20 Bn	1.97 Bn	229.00 Mn
3	Zoetis	32.50 Bn	30.56 Bn	1.62 Bn	-87.00 Mn
4	Takeda Pharmaceutical	27.56 Bn	23.49 Bn	4.39 Bn	-369.95 Mn
5	United Therapeutics	23.01 Bn	20.85 Bn	648.10 Mn	743.70 Mn
6	RedHill Biopharma	22.11 Bn	22.11 Bn	-	-
7	Viatris	20.41 Bn	18.61 Bn	1.16 Bn	277.40 Mn
8	Neurocrine Biosciences	17.77 Bn	16.45 Bn	800.70 Mn	-506.20 Mn
9	Elanco Animal Health	12.66 Bn	12.23 Bn	785.00 Mn	-60.00 Mn
10	Bespoke Extracts	1.12 Mn	1.11 Mn	234,175.00	-

Download Data